The Hormone Refractory Prostate Cancer (HRPCA) Market is expected to witness substantial growth, with a projected compound annual growth rate (CAGR) of 8.9% in terms of value, reaching USD 17.05 Billion by 2027 from USD 8.56 Billion in 2019. HRPCA, also known as Castration-Resistant Prostate Cancer, is a type of prostate cancer that tends to recur after androgen deprivation therapy, and it has become increasingly relevant in the prostate cancer market.

The global HRPCA market is set to expand significantly due to several factors, including a high unmet clinical need, low survival benefits, increasing prevalence rates, and emerging treatment advancements. Breakthrough treatments are expected to drive medical benefits and fuel market growth.

Get a free sample PDF of the report, visit @ https://www.reportsanddata.com/download-free-sample/2225

The International Classification of Diseases, Tenth Revision (ICD-10) is used for identifying patients suffering from hormone-refractory prostate cancer in medical records and for reimbursement purposes. Treatment options for HRPCA include Bicalutamide, ZYTIGA®, Abiraterone, and Lupron, but lack of awareness about new drugs and their potential side effects may hinder market growth.

Key players in the HRPCA Market include:

• AbbVie Inc.
• Acceleron Pharma Inc.
• AB Science SA
• AstraZeneca Plc.
• Astellas Pharma Inc.
• Boston Biomedical Inc.
• Dendreon Corporation
• Sanofi SA
• Johnson Johnson

Mergers and acquisitions have been common in the industry, with companies like Takeda Pharmaceuticals, Sanofi, and Bioverativ Inc. making significant acquisitions to strengthen their foothold in the market.

Several factors are expected to contribute to the promising market scenario, including a robust drug pipeline, increased patient awareness, the emergence of untapped non-metastatic CRPC (Castration-Resistant Prostate Cancer) space, and evolving treatment patterns. Moreover, the presence of a large undiagnosed patient population, rising disposable income, rapid urbanization, improved government funding towards cancer research, and growing awareness about prostate cancer will likely drive unparalleled market growth. However, uncertain reimbursement policies, premium pricing of CRPC drugs, and a lack of differentiation in the mechanism of drug delivery among approved and novel agents may hamper market growth.

To know more about the latest insights of the report, visit @

https://www.reportsanddata.com/request-latest-insight/2225

The HRPCA market is segmented based on agent type, treatment type, end-users, and regions. Radio-Pharmaceuticals accounted for a 14.1% market share in 2018 due to the unavailability of drugs required for Radiotherapy in the general consensus. Cytotoxic agents are expected to have the highest CAGR of 9.1% during the forecast period because of their availability and cost-effectiveness. Radiation Therapy is anticipated to experience the highest CAGR of 9.8% due to its use of intense energy beams to obliterate cancer cells. Chemotherapy held a substantial market share in 2019, with increasing cancer cases driving demand for cancer treatment medicine.

In terms of end-users, hospitals held the largest market share of 37.8% in 2018, owing to their well-resourced diagnostic rooms, higher purchasing power, the presence of skilled healthcare professionals, and improved health coverage for hospital-based healthcare services. Regionally, Europe is forecasted to experience a CAGR of 8.8% during the forecast period, driven by the efforts of EU countries to protect and improve the health of their populations. North America held the largest market share of 32.0% in 2018, with highly developed treatment scenarios and breakthroughs in technology and research driving market growth.

The report highlights that hormonal therapy accounted for the largest market share of around 59.0% in 2019 and is projected to grow at a rate of 8.4% from 2020 to 2027. Ambulatory Surgical Centers are expected to experience the highest CAGR of 10.0% during the forecast period due to the benefits of ambulatory treatment. The Asia Pacific region is forecasted to have the highest CAGR of 9.4% during the forecast period, driven by a large population base and increasing purchasing power parity.

In conclusion, the HRPCA market is poised for substantial growth due to various factors, such as breakthrough treatments, increasing awareness, and evolving treatment patterns. The market's potential lies in addressing the unmet clinical need and improving survival benefits. Companies are adopting various strategies to tap into this growing market and provide innovative products to meet the rising demand from end-users. With a focus on research and technological advancements, the HRPCA market is expected to witness sustained growth in the coming years.

Request a customized copy of the report @ https://www.reportsanddata.com/request-customization-form/2225

Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.  

Browse for more reports:

https://www.reportsanddata.com/report-detail/preimplantation-genetic-testing-market

https://www.reportsanddata.com/report-detail/cord-blood-banking-services-market

https://www.reportsanddata.com/report-detail/retinal-surgery-devices-market

https://www.reportsanddata.com/report-detail/medical-specialty-bags-market

https://www.reportsanddata.com/report-detail/teleradiology-market

https://www.reportsanddata.com/report-detail/electrophysiology-devices-market

About Reports and Data 

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W

(Head of Business Development)

Reports and Data | Web: www.reportsanddata.com

Direct Line: +1-212-710-1370

E-mail: sales@reportsanddata.com

Blogs | Press Release | Industry News | Our competencies

Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports

Browse More Latest Reports @ https://www.reportsanddata.com/report